ERMA Stock Overview
A pharmaceutical company, produces and supplies medical chewing gum and other nicotine products.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Enorama Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 5.22 |
| 52 Week High | SEK 10.50 |
| 52 Week Low | SEK 2.00 |
| Beta | 1.38 |
| 11 Month Change | 79.38% |
| 3 Month Change | 76.35% |
| 1 Year Change | 27.32% |
| 33 Year Change | -73.15% |
| 5 Year Change | -92.60% |
| Change since IPO | -33.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| ERMA | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | -1.5% | -1.8% | -4.2% |
| 1Y | 27.3% | 73.0% | 12.5% |
Return vs Industry: ERMA underperformed the Swedish Pharmaceuticals industry which returned 82.3% over the past year.
Return vs Market: ERMA exceeded the Swedish Market which returned 17% over the past year.
Price Volatility
| ERMA volatility | |
|---|---|
| ERMA Average Weekly Movement | 20.1% |
| Pharmaceuticals Industry Average Movement | 10.7% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in SE Market | 12.2% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: ERMA's share price has been volatile over the past 3 months.
Volatility Over Time: ERMA's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 5 | Annette Agerskov | www.enorama.se |
Enorama Pharma AB (publ), a pharmaceutical company, produces and supplies medical chewing gum and other nicotine products. It also offers nicotine pouches and medical cannabis products. Enorama Pharma AB (publ) was incorporated in 2006 and is based in Malmö, Sweden.
Enorama Pharma AB (publ) Fundamentals Summary
| ERMA fundamental statistics | |
|---|---|
| Market cap | SEK 213.63m |
| Earnings (TTM) | -SEK 42.47m |
| Revenue (TTM) | SEK 670.00k |
318.9x
P/S Ratio-5.0x
P/E RatioIs ERMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ERMA income statement (TTM) | |
|---|---|
| Revenue | SEK 670.00k |
| Cost of Revenue | SEK 4.93m |
| Gross Profit | -SEK 4.25m |
| Other Expenses | SEK 38.21m |
| Earnings | -SEK 42.47m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.04 |
| Gross Margin | -635.07% |
| Net Profit Margin | -6,338.66% |
| Debt/Equity Ratio | 2.0% |
How did ERMA perform over the long term?
See historical performance and comparison